MA30038B1 - Glycosylation d'anticorps dans la region variable - Google Patents
Glycosylation d'anticorps dans la region variableInfo
- Publication number
- MA30038B1 MA30038B1 MA31014A MA31014A MA30038B1 MA 30038 B1 MA30038 B1 MA 30038B1 MA 31014 A MA31014 A MA 31014A MA 31014 A MA31014 A MA 31014A MA 30038 B1 MA30038 B1 MA 30038B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibody
- glycosylated
- variable region
- asn
- heavy chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La présente invention concerne une préparation à base de molécule d'anticorps purifiée caractérisée en ce qu'au moins un site de liaison à l'antigène comprend une asparagine (Asn) glycosylée dans la région variable de la chaîne lourde (Vu). Plus spécifiquement, une composition pharmaceutique et une composition diagnostique comprenant ladite molécule d'anticorps et les mélanges d'anticorps sont mis à disposition, qui est/sont capable(s) de reconnaître spécifiquement le peptide (3-A4/A(beta)4. La présente invention concerne en particulier un mélange d'anticorps comprenant un ou deux sites de liaison à l'antigène glycosylé avec une asparagine (Asn) glycosylée dans la région variable de la chaîne lourde, c'est-à-dire des mélanges d'isoformes d'anticorps qui comprennent une Asn glycosylée dans la région variable de la chaîne lourde (VH). Des compositions ou préparations d'anticorps comprenant les isoformes d'anticorps spécifiquement glycosylés sont également décrites. En outre, les utilisations pharmaceutique et diagnostique pour ces anticorps sont mises à disposition. Les isoformes d'anticorps peuvent par exemple être utilisées dans l'intervention pharmaceutique lors d'une amyloïdogenèse ou de la formation de plaques amyloïdes et/ou dans le diagnostic de celles-ci.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05027090 | 2005-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30038B1 true MA30038B1 (fr) | 2008-12-01 |
Family
ID=37745986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31014A MA30038B1 (fr) | 2005-12-12 | 2008-06-09 | Glycosylation d'anticorps dans la region variable |
Country Status (34)
Country | Link |
---|---|
US (2) | US8906370B2 (fr) |
EP (2) | EP1960428B1 (fr) |
JP (1) | JP5145241B2 (fr) |
KR (2) | KR20080077132A (fr) |
CN (2) | CN102659943B (fr) |
AR (1) | AR057233A1 (fr) |
AT (1) | ATE517923T1 (fr) |
AU (1) | AU2006326301B2 (fr) |
BR (1) | BRPI0619605B8 (fr) |
CA (1) | CA2632828C (fr) |
CR (1) | CR10000A (fr) |
CY (1) | CY1114783T1 (fr) |
DK (1) | DK1960428T3 (fr) |
DO (1) | DOP2006000278A (fr) |
EC (1) | ECSP088524A (fr) |
ES (1) | ES2368591T3 (fr) |
HK (2) | HK1130066A1 (fr) |
IL (1) | IL191004A (fr) |
JO (1) | JO2824B1 (fr) |
MA (1) | MA30038B1 (fr) |
MY (1) | MY155286A (fr) |
NO (1) | NO346105B1 (fr) |
NZ (1) | NZ568241A (fr) |
PE (3) | PE20100748A1 (fr) |
PL (1) | PL1960428T3 (fr) |
PT (1) | PT1960428E (fr) |
RS (1) | RS52004B (fr) |
RU (1) | RU2438706C2 (fr) |
SI (1) | SI1960428T1 (fr) |
TW (1) | TWI382990B (fr) |
UA (1) | UA99097C2 (fr) |
UY (1) | UY30003A1 (fr) |
WO (1) | WO2007068429A1 (fr) |
ZA (1) | ZA200805038B (fr) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Aβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
KR101439828B1 (ko) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
PE20100748A1 (es) * | 2005-12-12 | 2010-11-12 | Hoffmann La Roche | Anticuerpo anti beta-4-amiloide que contiene asparagina glicosilada en la region variable de vh |
US20110070225A1 (en) * | 2006-11-12 | 2011-03-24 | Pierre Goldbach | Beta antibody parenteral formulation |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
HUE037060T2 (hu) * | 2007-06-29 | 2018-08-28 | Hoffmann La Roche | Javított immunglobulin-termeléshez vezetõ nehézlánc-mutáns |
BRPI0815576A2 (pt) * | 2007-08-20 | 2015-02-18 | Glaxo Group Ltd | Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo. |
PT2238166E (pt) | 2007-10-05 | 2014-02-11 | Genentech Inc | Utilização do anticorpo anti-amilóide beta em doenças oculares |
CN105126099A (zh) * | 2007-12-21 | 2015-12-09 | 弗·哈夫曼-拉罗切有限公司 | 抗体制剂 |
AU2009242453B2 (en) * | 2008-05-02 | 2014-12-04 | Seagen Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
US20140213465A1 (en) * | 2011-12-02 | 2014-07-31 | Plaxgen, Inc. | Plaque array methods and compositions for forming and detecting plaques |
US20120282654A1 (en) * | 2009-04-29 | 2012-11-08 | Schering Corporation | Antibody purification |
US20130116413A1 (en) * | 2009-12-29 | 2013-05-09 | Dr. Reddy's Laboratories, Inc. | Purification of proteins |
SG183369A1 (en) | 2010-03-03 | 2012-09-27 | Boehringer Ingelheim Int | Biparatopic abeta binding polypeptides |
WO2011130377A2 (fr) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Protéines de liaison à la bêta amyloïde |
RU2607368C2 (ru) | 2010-07-30 | 2017-01-10 | Ац Иммуне С.А. | Безопасные и функциональные гуманизированные антитела |
CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
US20140302532A1 (en) | 2011-04-12 | 2014-10-09 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
WO2013063284A1 (fr) * | 2011-10-25 | 2013-05-02 | Onclave Therapeutics | Formulations d'anticorps et procédés correspondants |
CA2860543C (fr) * | 2012-03-08 | 2018-04-24 | F. Hoffmann-La Roche Ag | Formulation d'anticorps anti-peptide abeta |
AU2013307406B2 (en) * | 2012-08-29 | 2018-03-15 | F. Hoffmann-La Roche Ag | Blood brain barrier shuttle |
CN102998454A (zh) * | 2012-12-11 | 2013-03-27 | 华中师范大学 | 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法 |
US9587022B2 (en) | 2012-12-18 | 2017-03-07 | The Rockefeller University | Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity |
US9790276B2 (en) | 2012-12-18 | 2017-10-17 | The Rockefeller University | Glycan-modified anti-CD4 antibodies for HIV prevention and therapy |
EP2956480B1 (fr) | 2013-02-13 | 2019-09-04 | Laboratoire Français du Fractionnement et des Biotechnologies | Anticorps anti-tnf alpha hautement galactosylés et leurs utilisations |
JP6169885B2 (ja) | 2013-05-07 | 2017-07-26 | 株式会社日立製作所 | 精製装置及び精製方法 |
KR102373930B1 (ko) | 2013-09-13 | 2022-03-11 | 제넨테크, 인크. | 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물 |
JP6546178B2 (ja) | 2013-09-13 | 2019-07-17 | ジェネンテック, インコーポレイテッド | 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法 |
CN105899192B (zh) | 2013-11-22 | 2019-08-13 | 国立大学法人东京大学 | 药物递送用载体、偶联物及含有这些成分的组合物以及它们的施予方法 |
CA2944402A1 (fr) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Navettes de la barriere hemato-encephalique contenant des anticorps reconnaissant l'alpha-synucleine |
WO2015165961A1 (fr) | 2014-04-29 | 2015-11-05 | Affiris Ag | Traitement et prévention de la maladie d'alzheimer |
IL302486A (en) | 2015-06-24 | 2023-06-01 | Hoffmann La Roche | Antibodies against the transnephrine receptor with adapted affinity |
CN107849087B (zh) * | 2015-08-21 | 2022-09-06 | 豪夫迈·罗氏有限公司 | 在亲和层析中减少宿主细胞蛋白的方法 |
AR106189A1 (es) * | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
PE20231655A1 (es) | 2015-10-02 | 2023-10-17 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso |
HUE057085T2 (hu) * | 2015-10-16 | 2022-04-28 | Hoffmann La Roche | Egy rendszer mûködtetésére szolgáló eljárás és egy rendszer |
WO2017079833A1 (fr) | 2015-11-09 | 2017-05-18 | The University Of British Columbia | Épitopes dans la région centrale de la bêta-amyloïde et anticorps conformationnels sélectifs associés |
EP3374383A4 (fr) | 2015-11-09 | 2019-05-15 | The University Of British Columbia | Épitopes de la bêta-amyloïde et anticorps associés |
WO2017079831A1 (fr) | 2015-11-09 | 2017-05-18 | The University Of British Columbia | Épitopes n-terminaux dans la bêta-amyloïde et anticorps conformationnellement sélectifs associés |
US10792477B2 (en) * | 2016-02-08 | 2020-10-06 | Orbusneich Medical Pte. Ltd. | Drug eluting balloon |
US20190114464A1 (en) * | 2016-03-10 | 2019-04-18 | Genomic Vision | Method of curvilinear signal detection and analysis and associated platform |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗-N3pGlu類澱粉β肽抗體及其用途 |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
CN110691592A (zh) * | 2017-05-30 | 2020-01-14 | 森永乳业株式会社 | 脑功能改善用组合物 |
EP3574020B1 (fr) | 2017-07-18 | 2024-05-15 | The University of British Columbia | Anticorps anti-bêta-amyloïde |
CN108048477A (zh) * | 2017-12-15 | 2018-05-18 | 南京理工大学 | 基于大肠杆菌表达系统的制备多肽的方法 |
EP3778875A1 (fr) | 2019-08-14 | 2021-02-17 | MaxiVax SA | Lignées de cellules myoblastes immortalisées et leurs utilisations |
JP2023535024A (ja) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗aベータ抗体 |
JP2023549809A (ja) | 2020-11-16 | 2023-11-29 | エフ. ホフマン-ラ ロシュ アーゲー | Fab高マンノースグリコフォーム |
TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
WO2022251048A1 (fr) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anticorps anti-amyloïde bêta et leurs utilisations |
CN114591429B (zh) * | 2022-05-07 | 2022-08-09 | 北京第一生物化学药业有限公司 | 结合β-淀粉样蛋白的抗体及其用途 |
CN117783359A (zh) * | 2023-12-28 | 2024-03-29 | 中国计量科学研究院 | 一种基于串联质谱的转基因蛋白多靶同检方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
CA1339014C (fr) | 1987-10-08 | 1997-03-25 | Ronald E. Majocha | Anticorps pour peptide a4-amyloide |
JP2780507B2 (ja) * | 1991-03-29 | 1998-07-30 | 松下電器産業株式会社 | 内燃機関用フィルタ再生装置 |
US5955317A (en) * | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
EP0683234B2 (fr) | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation |
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
GB9416007D0 (en) * | 1994-08-08 | 1994-09-28 | Erba Carlo Spa | Anthracyclinone derivatives |
US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
CN1191606A (zh) * | 1995-06-06 | 1998-08-26 | 干细胞治疗公司 | BL3造血干细胞上的糖蛋白gp105 |
DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
CN1279053C (zh) * | 1999-03-04 | 2006-10-11 | 普雷西斯药品公司 | 含有D-氨基酸的β-淀粉样肽聚集的调节因子 |
CA2376693C (fr) | 1999-06-16 | 2013-09-10 | Boston Biomedical Research Institute | Temoin immunologique de niveaux de .beta.-amyloide in vivo |
WO2001015655A2 (fr) | 1999-08-31 | 2001-03-08 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Peptides et substances, procedes et dispositif les utilisant pour diagnostiquer et traiter les troubles neurodegeneratifs |
US20020094335A1 (en) | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
WO2001039796A2 (fr) | 1999-11-29 | 2001-06-07 | Neurochem Inc. | Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides |
EP1125905A1 (fr) | 2000-02-16 | 2001-08-22 | Pepscan Systems B.V. | Synthèse de segments |
EP1257584B2 (fr) | 2000-02-24 | 2013-03-06 | Washington University St. Louis | Anticorps humanises sequestrant un peptide amyloide beta |
CA2313828A1 (fr) | 2000-08-01 | 2002-02-01 | Institut De Recherches Cliniques De Montreal/Ircm | Modification post-traduction de .beta.-secretase(bace) : les domaines cytosolyques pro- et transmembranaires ont des effets sur l'activite cellulaire et sur la production de la proteine .beta.amyloide |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
JP2005501220A (ja) | 2000-12-19 | 2005-01-13 | パラチン テクノロジーズ インク. | ペプチドおよび蛋白質の標的特異的折りたたみ部位の識別 |
ES2318006T3 (es) | 2001-04-30 | 2009-05-01 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el peptido beta-amiloide. |
ATE409047T1 (de) | 2001-04-30 | 2008-10-15 | Lilly Co Eli | Humanisierte antikörper |
EP1944040B1 (fr) * | 2001-08-17 | 2012-08-01 | Washington University | Procédé d'analyse pour la maladie d'Alzheimer |
JP2005503789A (ja) | 2001-08-17 | 2005-02-10 | イーライ・リリー・アンド・カンパニー | 抗Aβ抗体 |
AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
WO2004032868A2 (fr) | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methodes de traitement de la maladie d'alzheimer au moyen d'anticorps diriges contre le peptide $g(b)-amyloide et compositions les comprenant |
DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
PE20100748A1 (es) * | 2005-12-12 | 2010-11-12 | Hoffmann La Roche | Anticuerpo anti beta-4-amiloide que contiene asparagina glicosilada en la region variable de vh |
US20110070225A1 (en) * | 2006-11-12 | 2011-03-24 | Pierre Goldbach | Beta antibody parenteral formulation |
-
2006
- 2006-12-11 PE PE2010000560A patent/PE20100748A1/es active IP Right Grant
- 2006-12-11 UA UAA200808791A patent/UA99097C2/ru unknown
- 2006-12-11 PE PE2010000354A patent/PE20100684A1/es not_active Application Discontinuation
- 2006-12-11 RU RU2008128138/10A patent/RU2438706C2/ru active
- 2006-12-11 JP JP2008543748A patent/JP5145241B2/ja active Active
- 2006-12-11 BR BRPI0619605A patent/BRPI0619605B8/pt active IP Right Grant
- 2006-12-11 DO DO2006000278A patent/DOP2006000278A/es unknown
- 2006-12-11 KR KR1020087012289A patent/KR20080077132A/ko active Search and Examination
- 2006-12-11 AU AU2006326301A patent/AU2006326301B2/en active Active
- 2006-12-11 CN CN201210137369.8A patent/CN102659943B/zh active Active
- 2006-12-11 NO NO20082874A patent/NO346105B1/no unknown
- 2006-12-11 CN CN2006800463079A patent/CN101351476B/zh active Active
- 2006-12-11 EP EP06829502A patent/EP1960428B1/fr active Active
- 2006-12-11 EP EP11169488A patent/EP2377886A1/fr not_active Withdrawn
- 2006-12-11 WO PCT/EP2006/011914 patent/WO2007068429A1/fr active Application Filing
- 2006-12-11 SI SI200631096T patent/SI1960428T1/sl unknown
- 2006-12-11 JO JO2006444A patent/JO2824B1/en active
- 2006-12-11 CA CA2632828A patent/CA2632828C/fr active Active
- 2006-12-11 UY UY30003A patent/UY30003A1/es unknown
- 2006-12-11 DK DK06829502.1T patent/DK1960428T3/da active
- 2006-12-11 RS RS20110401A patent/RS52004B/en unknown
- 2006-12-11 PT PT06829502T patent/PT1960428E/pt unknown
- 2006-12-11 MY MYPI20081349A patent/MY155286A/en unknown
- 2006-12-11 ES ES06829502T patent/ES2368591T3/es active Active
- 2006-12-11 TW TW095146304A patent/TWI382990B/zh active
- 2006-12-11 US US12/086,309 patent/US8906370B2/en active Active
- 2006-12-11 AR ARP060105433A patent/AR057233A1/es unknown
- 2006-12-11 AT AT06829502T patent/ATE517923T1/de active
- 2006-12-11 NZ NZ568241A patent/NZ568241A/en unknown
- 2006-12-11 KR KR1020127010552A patent/KR101401159B1/ko active IP Right Grant
- 2006-12-11 PE PE2006001587A patent/PE20071002A1/es not_active Application Discontinuation
- 2006-12-11 PL PL06829502T patent/PL1960428T3/pl unknown
-
2008
- 2008-04-27 IL IL191004A patent/IL191004A/en active IP Right Grant
- 2008-05-20 CR CR10000A patent/CR10000A/es unknown
- 2008-06-09 MA MA31014A patent/MA30038B1/fr unknown
- 2008-06-10 ZA ZA200805038A patent/ZA200805038B/xx unknown
- 2008-06-10 EC EC2008008524A patent/ECSP088524A/es unknown
-
2009
- 2009-07-17 HK HK09106521.6A patent/HK1130066A1/xx unknown
- 2009-07-17 HK HK13103092.6A patent/HK1176075A1/xx unknown
-
2011
- 2011-09-16 CY CY20111100899T patent/CY1114783T1/el unknown
-
2014
- 2014-11-07 US US14/536,262 patent/US9272031B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30038B1 (fr) | Glycosylation d'anticorps dans la region variable | |
WO2003016466A3 (fr) | Anticorps anti-$g(a)$g(b) | |
MA27773A1 (fr) | Preparations d'anticorps et de proteines a forte concentration | |
Cordoba et al. | Non-enzymatic hinge region fragmentation of antibodies in solution | |
MA29606B1 (fr) | Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol | |
EP1111053A3 (fr) | Fragment peptidique de la protéine g du virus respiratoire syncytial, agent immunogène, composition pharmaceutique le contentant et procédé de préparation | |
CA2176840A1 (fr) | Association d'un compose a activite anti-microbienne et d'un monoalkylether de glycerol | |
MA30156B1 (fr) | Immunoglobulines | |
MA27952A1 (fr) | Anticorps neutralisants anti-ngf humains utilises comme inhibiteurs selectifs de la voie de ngf | |
WO2002086443A8 (fr) | Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon | |
TNSN07426A1 (fr) | Composition pharmaceutique comprenant un antiviral,un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l'eugenol le borneol et le carvacrol | |
EA200000331A1 (ru) | Фармацевтические композиции, содержащие белок плазмы | |
WO2006020580A3 (fr) | Variants de polypeptides synthetiques hyperglycosyles resistants a la protease, formulations orales et leurs procedes d'utilisation | |
TNSN07425A1 (fr) | Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol,l'eugenol, le thymol, le borneol, le carvacrol, et les ionones alpha-et-beta-. | |
MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
MA29378B1 (fr) | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer | |
MA28160A1 (fr) | Antagonistes du recepteur de la bradykinine b1 | |
MA31796B1 (fr) | Composes organiques | |
CA2296711A1 (fr) | Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique | |
NO943846D0 (no) | Angiotensin II antagonister mot forstyrrelser knyttet til svekket nerveledningshastighet, særlig diabetisk nevropati | |
CA2377519A1 (fr) | Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau | |
MA45890B2 (fr) | Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes | |
CA2072350A1 (fr) | Polypeptides impliques dans l'expression de la resistance aux antibiotiques glycopeptidiques | |
CA2539480A1 (fr) | Utilisation d'une dispersion colloidale organique de cerium et d'un element choisi parmi le rhodium et le palladium comme adjuvant de gazoles pour moteurs a combustion interne | |
FR3086946B1 (fr) | Procede ameliore pour la fabrication de polyamides transparents |